|
TAF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.02459999995475E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.20509999999874E-05 |
| Normal-vs-Stage2 |
3.959100E-03 |
| Normal-vs-Stage3 |
4.21520000015718E-07 |
| Normal-vs-Stage4 |
2.54889999995456E-06 |
| Stage1-vs-Stage2 |
8.719600E-01 |
| Stage1-vs-Stage3 |
8.972300E-02 |
| Stage1-vs-Stage4 |
1.137620E-01 |
| Stage2-vs-Stage3 |
1.995960E-01 |
| Stage2-vs-Stage4 |
2.387600E-01 |
| Stage3-vs-Stage4 |
9.902400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.78789999996754E-06 |
| Normal-vs-AfricanAmerican |
2.258100E-02 |
| Normal-vs-Asian |
6.638800E-04 |
| Caucasian-vs-AfricanAmerican |
5.273200E-01 |
| Caucasian-vs-Asian |
9.076600E-01 |
| AfricanAmerican-vs-Asian |
6.201200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.37909999997632E-06 |
| Normal-vs-Female |
4.88819999999723E-06 |
| Male-vs-Female |
3.986200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.765570E-04 |
| Normal-vs-Age(41-60Yrs) |
1.75094000000042E-05 |
| Normal-vs-Age(61-80Yrs) |
1.40169999995887E-06 |
| Normal-vs-Age(81-100Yrs) |
2.721300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.839200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.537000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.929610E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.994600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.179000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.093600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.926040E-02 |
| Classical-VS-Follicular |
1.053730E-02 |
| Classical-VS-Other |
2.671800E-01 |
| Classical-VS-Normal |
2.198000E-04 |
| Tall-VS-Follicular |
5.674600E-01 |
| Tall-VS-Other |
9.286400E-01 |
| Tall-VS-Normal |
1.80151999999989E-05 |
| Follicular-VS-Other |
8.234000E-01 |
| Follicular-VS-Normal |
2.55589999997863E-06 |
| Other-VS-Normal |
1.967990E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.86930000004126E-06 |
| Normal-vs-N1 |
5.79629999999387E-05 |
| N0-vs-N1 |
5.815200E-01 |
|
|
